Tabriz University of Medical Sciences Pharmaceutical Sciences 1735-403X 26 Covid-19 2020 11 30 NSAIDs and COVID-19: A New Challenging Area S49 S51 10.34172/PS.2020.41 EN Hananeh Baradaran https://orcid.org/0000-0002-5836-5681 Hadi Hamishehkar Haleh Rezaee https://orcid.org/0000-0002-4808-6179 Journal Article 10.34172/PS.2020.41 2020 03 31 2020 05 19 Considering the recent controversies regarding the use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in Coronavirus disease 2019 (COVID-19) patients, and due to the limited published data in this field, we reviewed currently available evidence for the use of NSAIDs in viral respiratory tract infections to help make decisions in this area. Currently, there is insufficient evidence to judge the safety and efficacy of NSAIDs in patients with COVID-19. According to the current evidence, acetaminophen is the choice treatment for symptomatic relief. If the patients’ symptoms are not controlled by acetaminophen, naproxen may be used as an alternative therapy.